Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a hold rating to a buy rating in a research report report published on Wednesday, January 10th. Zacks Investment Research currently has $10.00 price target on the biopharmaceutical company’s stock.
According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “
BLCM has been the topic of several other reports. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a report on Monday, September 18th. Jefferies Group restated a buy rating and set a $16.00 target price on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. BidaskClub upgraded shares of Bellicum Pharmaceuticals from a strong sell rating to a sell rating in a report on Thursday, January 4th. Finally, Raymond James Financial restated a buy rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Bellicum Pharmaceuticals has a consensus rating of Hold and a consensus price target of $23.50.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.74) by $0.03. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.03 million. During the same period last year, the business posted ($0.66) EPS. The firm’s revenue for the quarter was up 18.2% compared to the same quarter last year. equities research analysts expect that Bellicum Pharmaceuticals will post -2.93 EPS for the current year.
In related news, CFO Alan A. Musso sold 17,117 shares of the firm’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $9.33, for a total value of $159,701.61. Following the completion of the transaction, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Alan A. Musso sold 6,206 shares of the firm’s stock in a transaction on Monday, November 27th. The shares were sold at an average price of $9.89, for a total transaction of $61,377.34. The disclosure for this sale can be found here. Insiders sold 23,810 shares of company stock worth $225,657 over the last quarter. 18.77% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in BLCM. Point72 Asset Management L.P. bought a new position in shares of Bellicum Pharmaceuticals in the third quarter valued at $4,723,000. JPMorgan Chase & Co. boosted its position in Bellicum Pharmaceuticals by 10.2% during the second quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock worth $28,811,000 after purchasing an additional 227,668 shares during the period. Vanguard Group Inc. boosted its position in Bellicum Pharmaceuticals by 13.6% during the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock worth $14,092,000 after purchasing an additional 144,854 shares during the period. Numeric Investors LLC bought a new position in Bellicum Pharmaceuticals during the second quarter worth $1,137,000. Finally, Goldman Sachs Group Inc. boosted its position in Bellicum Pharmaceuticals by 223.5% during the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock worth $1,612,000 after purchasing an additional 95,336 shares during the period. 55.28% of the stock is owned by institutional investors and hedge funds.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.